MedTrace Logo

Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis

NCT05073926 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-07-15

No results posted yet for this study

Summary

Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus aureus in persons treated with rifampicin versus in persons treated with isoniazide. Through repeated swab cultures before, during, and after treatment the investigators will also investigate potential accumulation of mutations associated with rifampicin resistance over time. Finally, household contacts to persons with rifampicin-resistant S. aureus will be examined to investigate whether onward transmission of rifampicin-resistant S. aureus occurs within households.

Conditions

  • Latent Tuberculosis
  • Staphylococcus Aureus

Interventions

OTHER

No intervention is part of the study protocol

No intervention is part of the study protocol. The choice of treatment for latent tuberculosis is is made by the treating physician.

Sponsors & Collaborators

  • Region Skane

    lead OTHER

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05073926 on ClinicalTrials.gov